title: [Clinical study of levofloxacin 500 mg qd in the treatment of cervicitis and intrauterine infections caused by Chlamydia trachomatis].
abstract: The clinical efficacy and safety of levofloxacin (LVFX) 500mg qd were evaluated in female patients with cervicitis with Chlamydia trachomatis and intrauterine infections. LVFX was administered orally at 500 mg qd for 7 days. Bacteriological efficacy was 94.4% (17/18) and clinical efficacy was 100% (16/16) at 14 to 21 days after the end of treatment in cervicitis. On the other hand, bacteriological efficacy and clinical efficacy at the end of treatment in intrauterine infections were 68.8% (11/16) and 94.7% (18/19), respectively. For safety, adverse drug reactions occurred in 9 of 43 patients (20.9%), i.e., increased y-GTP in 2 patients, glucose urine present in 2, and each of all other adverse reactions occurred in 1. All adverse drug reactions observed were either mild or moderate. Results suggested that LVFX 500 mg qd was effective and safe in the treatment of cervicitis with Chlamydia trachomatis and intrauterine infections.
authors: Department of Infection Control and Prevention, Aichi Medical University Graduate School of Medicine.
authors: Hiroshige
authors: H
authors: Mikamo
authors: Yuka
authors: Y
authors: Yamagishi
authors: Keiichi
authors: K
authors: Takahashi
authors: Koji
authors: K
authors: Izumi
authors: Shinji
authors: S
authors: Hoshina
authors: Ken
authors: K
authors: Nakabe
authors: Michihisa
authors: M
authors: Fujiwara
authors: Makoto
authors: M
authors: Yoshimura
authors: Yukiko
authors: Y
authors: Ando
authors: Motoko
authors: M
authors: Kurashima
authors: Chisato
authors: C
authors: Kinoshita
authors: Masuo
authors: M
authors: Yoshioka
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002690:Chlamydia Infections; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D004334:Drug Administration Schedule; D004716:Endometritis / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D006029:Glycosuria / Q000139:chemically induced; D006160:Guanosine Triphosphate / Q000097:blood; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000008:administration & dosage* / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome; D002575:Uterine Cervicitis / Q000188:drug therapy* / Q000382:microbiology*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D006160:Guanosine Triphosphate; D015242:Ofloxacin